Refine by
Cell Therapy Articles & Analysis
488 news found
(TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), an autologous (patient’s own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, under ...
(TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce ...
(“Hemostemix” or the “Company”) (TSXV: HEM, OTCQB: HMTXF; FSE:2VF0), the leading autologous (patient’s own) stem cell therapy company treating no-option patients in Florida suffering in pain from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease and Angina, is pleased to announce its webinar topic for Thursday, August ...
Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...
About Protheragen Protheragen specializes in providing a range of preclinical research services for rare disease research, addressing many of the challenges encountered in drug discovery and development. Its end-to-end rare disease therapy development solutions cover a full package of therapeutic development services, which include small molecule, cell ...
The APIs in chemotherapy work by interfering with the cell division mechanism to suppress cancer cell growth. In the meantime, targeted therapies target individual molecules or genes, sparing healthy tissues from collateral damage. The immunotherapy APIs energize the immune system to target cancer cells; hormone ...
In addition to a variety of experimental animals including mice, rats, rabbits, and monkeys, Ace Therapeutics can assist worldwide clients in constructing custom animal models using techniques such as environmental enrichment, gene editing, dietary modifications, or drug therapies. Moreover, the company can also provide researchers with cardiac organoid models and human induced ...
As of the latest research, several experimental gene therapies for glaucoma are in various stages of development, from preclinical studies to early-phase clinical trials. ...
Additionally, CD Formulation offers Peptide Drug Conjugates (PDCs) service, which utilize homing peptides to streamline drug delivery to overexpressed protein receptors on tumor cells. This not only enhances the efficacy of the drug by improving tumor penetration but also significantly lowers immunogenicity and production costs. ...
Idiopathic pulmonary fibrosis (IPF) remains a devastating condition with limited treatment options, often leading to a grim prognosis. However, a recent study by Milman-Krentsis (2024) offers a beacon of hope, demonstrating the potential of lung cell transplantation as a therapeutic intervention for lung fibrosis. Utilizing two distinct mouse models—one treated with bleomycin and another ...
Advanced Instruments, a leading provider of analytical instruments and services for clinical and biopharmaceutical laboratories, is proud to announce the expansion of its Artel portfolio’s direct presence in Austria, France, Germany, and Switzerland. This strategic move underscores Advanced Instruments’ commitment to providing unparalleled access to their liquid volume verification ...
Almost anyone with a weakened or suppressed immune system could be at a heightened risk of developing an invasive mold infection (IMI). Two of the most common IMIs include invasive aspergillosis and invasive mucormycosis. The Centers for Disease Control and Prevention (CDC) warns that IMIs can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to ...
ADCs are an expanding class of therapies designed to target and kill tumor cells while sparing healthy cells. These very targeted therapies are available to patients with specific indications, including HER2 and FOLR1 expressing tumors. ...
ByTempus
Longeveron's foundation in cutting-edge cellular therapy research, coupled with the promise of Lomecel-BTM, positions us to profoundly impact patients' lives for the better by addressing numerous unmet medical needs with U.S. market potential opportunities of up to approximately $10-$18 billion. ...
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. ...
CELLINK Vivoink is optimized for superior printability, mechanical stability, and cell viability, making it a game-changer in the bioprinting industry. Cell-based therapy and tissue engineering have long held the promise of transforming healthcare by enabling the regeneration of damaged tissues and the development of advanced disease models. ...
ByCELLINK
Anyone with a weakened or suppressed immune system could be at heightened risk of developing an invasive mold infection. The Centers for Disease Control and Prevention (CDC) warns that these types of infections can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to advise physicians to keep invasive mold infections in mind when treating people ...
CAR-T (chimeric antigen receptor T-cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies involve genetically modifying a patient's own immune cells to recognize and attack cancer cells more efficiently. ...
Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen Bio Inc, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. The Registration Statement contains a preliminary proxy statement and ...
CD BioGlyco, a biotechnology company that provides multi-omics analysis of cancer cell glycolysis including genomics, proteomics, metabolomics and metabolic fluxomics, now offers analysis of glycolytic enzymes in cancer cells, enabling thorough understanding of cancer cell glycolysis pathways. ...